Across TCGA pan-cancer cohorts, ZNF691 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of ZNF691’s most consistent transcriptional readouts.
The strongest signal is observed in lung adenocarcinoma (LUAD), where ZNF691 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ZNF691 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.
LUAD, LSCC, and PDAC are the cancer types where ZNF691 tumor–normal differential expression is most reproducible.